1. Search Result
Search Result
Results for "

complex V

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

4

Natural
Products

1

Recombinant Proteins

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-152949

    Myosin Neurological Disease
    Myosin V-IN-1 (compound 8) is a potent and selective Myosin V inhibitor, with a Ki of 6 μM. Myosin V-IN-1 shows acute inhibition of myosin V. Myosin V-IN-1 slows the actin-activated myosin V ATPase by specifically inhibiting ADP release from the actomyosin complex .
    Myosin V-IN-1
  • HY-173629

    Ras Apoptosis Cancer
    RMC-5127 is an orally active and brain-penetrant mutant-selective tri-complex RAS G12V inhibitor. RMC-5127 non-covalently binds to cyclophilin A (CypA), forming a binary complex that engages RASG12V(ON) to form a high-affinity tri-complex, sterically inhibiting RAS binding . RMC-5127 inhibits the RAS pathway in KRAS G12V mutant cancer cells, reducing cell proliferation and inducing apoptosis. RMC-5127 is promising for research of cancers with RAS mutations, such as non-small cell lung cancer .
    RMC-5127
  • HY-130257

    PROTACs Cancer
    CP5V is a PROTAC connected by ligands for von Hippel-Lindau and CDK, which specifically degrades Cdc20 by linking Cdc20 to the VHL/VBC complex for ubiquitination followed by proteasomal degradation. CP5V induces mitotic inhibition and suppresses cancer cell proliferation .
    CP5V
  • HY-N6782
    Oligomycin
    Maximum Cited Publications
    80 Publications Verification

    Oxidative Phosphorylation ATP Synthase Fungal Antibiotic Infection Cancer
    Oligomycin, an antifungal antibiotic, is an inhibitor of H +-ATP-synthase. Oligomycin blocks oxidative phosphorylation and the electron transport chain. Oligomycin inhibits HIF-1alpha expression in hypoxic tumor cells .
    Oligomycin
  • HY-E70542

    Biochemical Assay Reagents Cardiovascular Disease
    Bovine Factor V/Va can be purified from fresh bovine plasma and used as a source of V/Va in the prothrombinase complex.
    Bovine Factor V/Va
  • HY-E70778

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET V804L is a mutant of RET. RET V804L Recombinant Human Active Protein Kinase is a recombinant RET V804L protein that can be used to study RET V804L-related functions .
    RET V804L Recombinant Human Active Protein Kinase
  • HY-E70779

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET V804M is a mutant of RET. RET V804M Recombinant Human Active Protein Kinase is a recombinant RET V804M protein that can be used to study RET V804M-related functions .
    RET V804M Recombinant Human Active Protein Kinase
  • HY-E70777

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET V804E is a mutant of RET. RET V804E Recombinant Human Active Protein Kinase is a recombinant RET V804E protein that can be used to study RET V804E-related functions .
    RET V804E Recombinant Human Active Protein Kinase
  • HY-W614725

    APC Ligands for Target Protein for PROTAC Cancer
    Apcin-A monohydrochloride, an Apcin derivative, is an anaphase-promoting complex (APC) inhibitor. Apcin-A monohydrochloride interacts strongly with Cdc20, and inhibits the ubiquitination of Cdc20 substrates. Apcin-A monohydrochloride can be used to synthesize the PROTAC CP5V (HY-130257) .
    Apcin-A monohydrochloride
  • HY-125714

    Mitochondrial Metabolism ATP Synthase Neurological Disease Cancer
    Isoapoptolidin is a mitochondrial F0F1-ATPase inhibitor (Ki>100 μM, selective for mitochondrial complex V). Isoapoptolidin is promising for research of mitochondrial energy metabolism-related diseases (e.g., cancer, neurodegeneration) .
    Isoapoptolidin
  • HY-12343

    CID-53347902

    Potassium Channel Cardiovascular Disease
    ML277 (CID-53347902) is a potent and selective activator of K(v)7.1 (KCNQ1) potassium channel activator (EC50=270 nM), rescues function of pathophysiologically important mutant channel complexes in human induced pluripotent stem cell-derived cardiomyocytes .
    ML277
  • HY-109098

    LYC30937

    ATP Synthase Apoptosis Inflammation/Immunology
    Parimifasor (LYC-30937) is an orally active agent for inflammatory bowel disease. Parimifasor targets F1F0-ATPase. Parimifasor acts on respiratory complex V, slows ATP production and induces Apoptosis. Parimifasor can be used in the research of inflammatory bowel disease .
    Parimifasor
  • HY-155474

    Apoptosis Cancer
    Me4Phen (compound 3) is an oxygen rhenium (V) complex that depletes mitochondrial membrane potential and upregulates intracellular reactive oxygen species (ROS), leading to endoplasmic reticulum stress-mediated necrosis of cancer cells. Me4Phen is highly lipophilic and effectively overcomes Cisplatin (HY-17394) resistance in a variety of cancer cells .
    Me4Phen
  • HY-178042

    Ras Cancer
    SS-3091 is a pan KRas inhibitor. SS-3091 binds to the interaction interfaces of KRas, destabilizing the ARaf/KRas complex and thereby influencing downstream signaling transduction. SS-3091 has significant anticancer and antiproliferation activities against the KRas G12D, G12C, G12V, and G12S mutants in various cancer cells .
    SS-3091
  • HY-W854844B

    Molecular Glues E1/E2/E3 Enzyme Cancer
    JP-2-196 hydrochloride is a covalent molecular glue degrader targeting RNF126. JP-2-196 hydrochloride induces the formation of a ternary complex between RNF126 and target proteins (e.g., BRD4, AR-V7), promoting their ubiquitination and proteasomal degradation. JP-2-196 hydrochloride is promising for research of cancers (e.g., prostate cancer, leukemia) .
    JP-2-196 hydrochloride
  • HY-173364

    BAK-04-212

    BCL6 Cancer
    EB-TCIP (BAK-04-212) is a bivalent molecule comprised of AP1867 (HY-114434) and BI-3812 (HY-111381). EB-TCIP can form a reversible ternary complex between FKBP F36V and BCL6 BTB. EB-TCIP recruits FKBP12 F36V-tagged EWS/FLI1 to DNA sites bound by the transcriptional regulator BCL6, leading to rapid expression of BCL6 target genes (eg: SOCS2 and CXCL11). EWS/FLI1 is a fusion transcription factors in Ewing sarcoma. EB-TCIP can be used for research of deregulated transcription in cancer .
    EB-TCIP
  • HY-126634

    Others Infection
    Lyngbyatoxin B is a complex compound in a versatile biosynthetic pathway from the marine cyanobacterium Moorea producens. By heterologously expressing the lyngbyatoxin biosynthetic pathway in Escherichia coli, lyngbyatoxin A (25.6 mg/L) and its precursor indolactam-V (150 mg/L) were successfully produced. This approach confirmed the biosynthetic route of lyngbyatoxin and laid a chemical foundation for future pathway engineering. In addition, the successful production of lyngbyatoxin A in E. coli opens the possibility for heterologous expression and characterization of other cyanobacterial natural products.
    Lyngbyatoxin B
  • HY-156498
    RMC-7977
    5+ Cited Publications

    Ras ERK Raf Ribosomal S6 Kinase (RSK) AMPK Apoptosis PARP Cancer
    RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (Kd = 195 nM) and KRAS (G12V) (Kd = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRAS G12C cancer models, and demonstrates good tolerability across various RAS cancer models .
    RMC-7977
  • HY-N2787
    8-​Prenylnaringenin
    1 Publications Verification

    PI3K Akt AMPK Sirtuin Reactive Oxygen Species (ROS) SOD Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology Cancer
    8-Prenylnaringenin is an orally active prenyl flavonoid. 8-Prenylnaringenin can be isolated from the hop spike Humulus lupulus. 8-Prenylnaringenin activates the PI3K/Akt pathway and the AMPK pathway, upregulates OXPHOS complexes (II, III, and V) and Sirt1, and reduces ROS production and SOD activity. 8-Prenylnaringenin improves muscle atrophy and obesity and inhibits angiogenesis. 8-Prenylnaringenin exhibits anticancer activity against glioblastoma and colon cancer. 8-Prenylnaringenin also has LH/FSH regulatory activity. 8-prenylnaringenin may be used in bone health research .
    8-​Prenylnaringenin
  • HY-130841

    APC Ligands for Target Protein for PROTAC Cancer
    Apcin-A is a small molecule inhibitor that selectively targets the cell division cycle protein Cdc20 and is a derivative of Apcin (HY-110287). Apcin-A competitively binds to the D-box binding pocket of Cdc20 and inhibits substrate ubiquitination mediated by the anaphase promoting complex APC/C-Cdc20. Apcin-A also blocks the binding of Cdc20 to substrates (such as securin and cyclin B1), inhibiting anaphase initiation and cell cycle exit. Apcin-A can promote or prolong mitotic slippage in coordination with p31 comet under conditions of high spindle assembly checkpoint (SAC) activity. Apcin-A can be used to develop anti-mitotic drugs and overcome tumor chemotherapy resistance. Apcin-A can be used to synthesize PROTAC CP5V (HY-130257)[1][2][3].
    Apcin-A
  • HY-169385

    AUTOTACs Androgen Receptor Cancer
    ATC-324 is an bivalent AR (Androgen Receptor) degrader based on the protein degradation technology platform AUTOphagy-TArgeting Chimera (AUTOTAC). ATC-324 induces the formation of AR/p62 complex, leading to autophagy-lysosomal degradation of AR. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa . ATC-324 is composed of target-binding ligand (TBL) Enzalutamide (HY-70002) and p62/SQSTM1 autophagy-targeting ligand (ATL) YT 6-2 analog-1 (HY-169386), connected by Boc-NH-PEG4-CH2CH2NH2 (HY-W008352). Among them, the active control of the target protein ligand is Enzalutamide carboxylic acid (HY-70002B), and the conjugate composed of the autophagy-targeting ligand and the linker is YT 6-2-PEG3-C2-NH2 (HY-169387).
    ATC-324

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: